RxDoctor Payments Data

Tomas Vybiral, MD

Cardiovascular Disease · Elkin, NCNPI 1740285824

Payments from drug & device makers

$561in general payments, 2019–2025

Across 29 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$150
  • Pfizer$80
  • Vital Connect, Inc$80
  • Novo Nordisk$68
  • GSK$58
  • Abbott$28
  • plus $98 from 5 others

What the payments were for

  • Food & beverage$561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$561 in reported general payments places this provider in the 20th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$429,778
Medicare patients
745
Services billed
4,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban959$1,096,555
XareltoRivaroxaban110$111,316
OzempicSemaglutide82$101,623
FarxigaDapagliflozin Propanediol72$75,043
JanuviaSitagliptin Phosphate51$55,408
JardianceEmpagliflozin39$54,284
Repatha SureclickEvolocumab63$43,409
EntrestoSacubitril/Valsartan24$40,976
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$38,304
LinzessLinaclotide35$35,389
TrulicityDulaglutide32$34,866
MounjaroTirzepatide31$33,131
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$25,563
MyrbetriqMirabegron21$23,697
Praluent PenAlirocumab31$22,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$80$1,102,108974 claims
Johnson & JohnsonXarelto$150$111,316110 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$28$109,399136 claims
Novo NordiskOzempic$68$101,62382 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$18$69,98665 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$58$53,36590 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Elkin

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →